Femoral Head Osteonecrosis in Pediatric and Young Adult Patients With Leukemia or Lymphoma
Authors:
- 20 April 2007
- journal article
- pediatric oncology
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 25 (12) , 1525-1531
Abstract
Purpose: Osteonecrosis of the capital femoral epiphysis is a significant late toxicity of treatment for childhood leukemia and lymphoma. We determined clinical and imaging risk factors predicting clinical joint outcomes of femoral head osteonecrosis in pediatric patients with leukemia or lymphoma. Patients and Methods: We reviewed retrospectively medical records and magnetic resonance imaging scans of 80 patients with osteonecrosis of the capital femoral epiphysis. Logistic regression was used to examine relationships between risk factors and outcomes of joint surface collapse and arthroplasty. We used Kaplan-Meier survival curves to display the time to joint surface collapse and arthroplasty based on selected predictors. Results: Median time between primary diagnosis and diagnosis of osteonecrosis of the hip was 1.7 years (range, 0.1 to 17.5 years). Twenty-three patients (29%) underwent arthroplasty in 36 hips at a mean of 1.3 years (range, 0.5 to 8.6 years) after diagnosis of osteonecrosis. Median age at time of first arthroplasty was 20.1 years (range, 15.1 to 35.4 years). Joint outcome of osteonecrosis was predicted solely by lesion size at diagnosis of osteonecrosis. The worst prognosis was associated with lesions occupying more than 30% of the femoral head volume; 80% of hips with these lesions collapsed within 2 years of diagnosis and 50% required arthroplasty. Conclusion: Lesion size of osteonecrosis is the best predictor of clinical joint outcome of hip osteonecrosis in survivors of pediatric hematologic malignancy. Lesions occupying more than 30% of the femoral head have high likelihood of joint deterioration necessitating arthroplasty at a young age.Keywords
This publication has 23 references indexed in Scilit:
- Treatment of Acute Lymphoblastic LeukemiaNew England Journal of Medicine, 2006
- Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research HospitalBlood, 2004
- Osteonecrosis: A treatment related toxicity in childhood acute lymphoblastic leukemia (ALL)—experiences from trial ALL‐BFM 95Pediatric Blood & Cancer, 2004
- Pharmacogenetic Risk Factors for Osteonecrosis of the Hip Among Children With LeukemiaJournal of Clinical Oncology, 2004
- Bone mineral density and osteonecrosis in survivors of childhood allogeneic bone marrow transplantationBone Marrow Transplantation, 2004
- Joint Preserving Surgery for Osteonecrosis and Osteochondral Defects after Chemotherapy in ChildhoodKlinische Padiatrie, 2003
- Avascular necrosis in long‐term survivors after allogeneic or autologous stem cell transplantationCancer, 2003
- Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer GroupBlood, 2003
- Volumetric analysis of osteonecrosis of the femurThe Journal of Bone and Joint Surgery. British volume, 2001
- The Use of Glucocorticoids in Acute Lymphoblastic Leukemia of Childhood Molecular, Cellular, and Clinical ConsiderationsJournal of Pediatric Hematology/Oncology, 1995